Eli Lilly (LLY) Liabilities from Discontinued Operations (2018)

Eli Lilly (LLY) reported Liabilities from Discontinued Operations of 2742300000.0 for Q4 2018.

Eli Lilly (LLY) Liabilities from Discontinued Operations (2018) Analysis & Trends

Eli Lilly has reported Liabilities from Discontinued Operations for 1 years, with the latest figure at 2742300000.0 in Q4 2018.

For the quarter ending Q4 2018, Liabilities from Discontinued Operations changed N/A year-over-year to 2742300000.0; the trailing twelve-month figure through Dec 2018 stood at 2742300000.0 (changed N/A YoY), and the FY2018 full-year result was 2742300000.0, changed N/A from the prior year.
Liabilities from Discontinued Operations for Q4 2018 stood at 2742300000.0.
The five-year high for Liabilities from Discontinued Operations was 2742300000.0 in Q4 2018, with the low at 2742300000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn
10	Novartis Ag	108.28 Bn	107.60 Bn	-

Download Data

Date	Value
Dec 31, 2018	2.74 Bn
Dec 31, 2018	2.74 Bn